<DOC>
	<DOCNO>NCT00129805</DOCNO>
	<brief_summary>Sarpogrelate ( MCI-9042 ) antiplatelet drug decrease 5-hydroxytryptamine ( 5-HT ) level platelet via blockade 5-HT2 receptor ; use atherosclerotic peripheral arterial disease . S-ACCESS randomized , double-blinded trial compare relative efficacy sarpogrelate ( 100mg three time daily ) aspirin ( 81mg daily ) 1510 patient recent cerebral infarction . Patients follow 0.9 3.5 year . The primary endpoint recurrence cerebral infarction ; relative safety also assess .</brief_summary>
	<brief_title>Sarpogrelate-Aspirin Comparative Clinical Study Efficacy Safety Secondary Prevention Cerebral Infarction ( S-ACCESS )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Sarpogrelate</mesh_term>
	<criteria>Cerebral infarction except cardiac source embolism Onset ≧ 1 week ≦ 6 month randomization Neurological sign persist ≧ 1 day onset Computed tomography ( CT ) magnetic resonance imaging ( MRI ) detection responsible site Age ≧ 20 year Systolic pressure ≦ 180 mmHg ; diastolic pressure ≦ 110 mmHg Functional outcome randomization : Modified Rankin Scale = 4 , 5 Previous plan vascular surgery cerebral infarction History intracranial hemorrhage History systemic bleeding , history bleed diathesis coagulopathy Severe complication ( renal hepatic insufficiency , heart failure , hemopathy , etc . ) Pregnant possibly pregnant woman , nurse mother History sarpogrelate aspirin sensitivity Treating malignant tumor treat within 5 year Current peptic ulceration</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>